Cryopreservation of gonadal tissue for fertility preservation in patients with disorders of sex development
Official title: Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
Run by University of Colorado, Denver · NCT06518746 · Data updated 2026-11-12
This study is testing if freezing gonadal tissue can help young people with disorders of sex development preserve their fertility and hormonal health before surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 30 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Status | Recruiting |
| Started | August 16, 2021 |
| Main results expected | December 30, 2030 |
| Study ends | June 30, 2031 |
| Registry record updated | September 18, 2025 |
| Trial ID | NCT06518746 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals under 30 years of age diagnosed with a disorder of sex development who are at risk for malignancy in their gonadal tissue.
✕Probably not a fit
Patients who are likely to retain inherent fertility and reproductive function or those with significant cognitive delays may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients with disorders of sex development (DSD) who are at risk of infertility or malignancy due to abnormal gonadal development. It aims to assess the safety and efficacy of gonadal tissue cryopreservation as a method for preserving fertility and restoring hormonal function. Participants under 30 years of age who require gonadectomy for clinical reasons will be included, while those with inherent fertility or significant cognitive issues will be excluded. The study seeks to provide a viable fertility preservation option for this unique patient population.
Why it matters
Potential benefit: If successful, this approach could offer a critical fertility preservation option for individuals with disorders of sex development at risk of infertility.
How similar studies have gone: While this approach is novel for the specific population of patients with DSD, similar cryopreservation techniques have shown promise in other fertility preservation contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \< 30 years of age * Individuals diagnosed with a disorder of sex development who have any risk for malignancy in their gonadal tissue and will have their gonads removed for a clinical indication * Individuals diagnosed with a disorder of sex development who are at risk of primary ovarian insufficiency (POI) due to an underlying genetic condition Exclusion Criteria: * Pregnancy * Patients likely to retain inherent fertility and reproductive function * Patients deemed high risk for perioperative complications * Patients 7-17 years of age unable to provide assent (i.e. significant psychiatric problems/cognitive delay) * Patients 18 and older unable to provide consent (i.e. significant psychiatric problems/cognitive delay)
Where it's running
-
University of Colorado
Aurora, Colorado, United States Recruiting
Study contacts
- Principal investigator: Kristine Corkum, MD — University of Colorado, Denver
- Study coordinator: Kristine Corkum, MD
- Email: Kristine.Corkum@childrenscolorado.org
- Phone: (720) 777-6174
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.